Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Waters Corporation (NYSE:WAT) will announce its Q1 2023 financial results on May 9, 2023, at 8:00 a.m. Eastern Time. A live webcast will be accessible through the company’s investor relations website, with a replay available until May 23, 2023. Waters Corporation has a rich history of over 60 years in analytical instruments, including chromatography and mass spectrometry, and operates in more than 35 countries with over 8,200 employees globally.
Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute IVD System, enhancing its MassTrak IVD portfolio. This state-of-the-art system is the most sensitive benchtop tandem quadrupole mass spectrometer for clinical applications, boasting up to five times the sensitivity of its peers. It features a 45% smaller design and consumes 50% less nitrogen gas and electricity, making it environmentally sustainable. The Xevo TQ Absolute IVD allows laboratories to analyze trace-level analytes in smaller samples, thereby expanding testing capabilities for less-invasive assays. The system aims to improve patient care through advanced diagnostic options.